Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $154 | $295 | $74 | $222 |
| Short-Term Investments | $429 | $282 | $410 | $225 |
| Receivables | $14 | $1 | $4 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $6 | $2 | $1 | $1 |
| Total Curr. Assets | $603 | $581 | $490 | $448 |
| Property Plant & Equip (Net) | $2 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $120 | $30 | $5 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $1 | $1 | $0 |
| Total NC Assets | $122 | $32 | $7 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $725 | $613 | $497 | $450 |
| Liabilities | – | – | – | – |
| Payables | $12 | $10 | $4 | $6 |
| Short-Term Debt | $13 | $1 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $79 | $47 | $24 | $15 |
| Total Curr. Liab. | $104 | $58 | $29 | $21 |
| LT Debt | $333 | $1 | $1 | $21 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $333 | $1 | $1 | $21 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $2 | $1 | $1 |
| Total Liabilities | $437 | $59 | $30 | $41 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,221 | -$902 | -$693 | -$544 |
| AOCI | $0 | $0 | -$1 | $0 |
| Other Equity | $1,509 | $1,456 | $1,161 | $952 |
| Total Equity | $288 | $554 | $467 | $408 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $725 | $613 | $497 | $450 |
| Net Debt | $192 | -$294 | -$73 | -$201 |